RAPP
$27.08-0.38 (-1.38%)
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders.
Recent News
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China
In March 2026, Rapport Therapeutics granted Tenacia Biotechnology exclusive rights to develop and commercialize its clinical-stage epilepsy and bipolar candidate RAP-219 across Greater China, in a deal including a US$20 million upfront payment and up to approximately US$308 million in potential milestones plus tiered royalties. The agreement effectively turns Greater China into a major development hub for RAP-219, adding Phase 3 trial sites in China while allowing Rapport to retain rights in...
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal
Arcellx develops cell-based immunotherapies for cancer, leveraging proprietary platforms to address high unmet needs in oncology.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter
Praxis Precision Medicines develops clinical-stage therapies for neurological disorders, targeting major unmet needs in CNS therapeutics.
We're Not Very Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. Indeed, Rapport Therapeutics...